FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150970912> ?p ?o ?g. }

• W2150970912 abstract "It was with great interest that we read the results presented by Professors La-He Jearn and Th ink-You Kim regarding the infl uence of anti-cyclic citrullinated peptide (CCP) on anticentromere antibody (ACA)positive patients suff er ing from rheumatoid arthritis (RA) [1]. Th eir fi ndings explore the eff ect of ACA positivity in a patient group diff erent from the cohort of primary Sjogren syndrome (SS) patients we chose to study [2]. Due to the diff erent study population and the retrospective nature of our work, our data do not include measurement of anti-CCP antibodies. Anti-CCP antibodies provide a specifi c tool for the diagnosis of RA that seems to correlate with disease severity and early erosive disease. Th e method has a 70% sensitivity for RA [3], which is consistent with the 70.6% positivity of anti-CCP reported by Jearn and Kim among their ACA-positive RA group. A striking point in the results presented by the two colleagues is the high prevalence (21%) of RA among ACA-positive patients, which is not in line with previous publications that have reported a prevalence of 5 to 6% [4]. In a general population of RA patients with variable antibody background, interstitial lung disease and Raynaud’s phenomenon have a reported prevalence in the range of 7.7 to 10% [5]. Jearn and Kim found 4 (11.8%) patients with interstitial lung disease and 1 (10%) patient with Raynaud’s phenomenon out of 34 ACA-positive RA patients. Despite the fact that the numbers are small and do not allow for safe conclusions, both results are well in the range reported in the literature for unselected RA patients and unrelated to the anti-CCP positivity. Th is could, in a sense, indicate that the presence of ACA or anti-CCP antibodies in RA does not aff ect the clinical features in question. We believe that an extended presentation of the results found by Jearn and Kim would be very interesting and more than welcome. We also think that evaluation of our ACA-positive SS patients for anti-CCP reactivity should be interesting." @default.
• W2150970912 created "2016-06-24" @default.
• W2150970912 creator A5015399688 @default.
• W2150970912 creator A5059993695 @default.
• W2150970912 date "2010-10-01" @default.
• W2150970912 modified "2023-10-06" @default.
• W2150970912 title "The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients: authors' response" @default.
• W2150970912 cites W2015297297 @default.
• W2150970912 cites W2022441502 @default.
• W2150970912 cites W2090216780 @default.
• W2150970912 cites W2097009871 @default.
• W2150970912 cites W2119933186 @default.
• W2150970912 doi "https://doi.org/10.1186/ar3154" @default.
• W2150970912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2991019" @default.
• W2150970912 hasPublicationYear "2010" @default.
• W2150970912 type Work @default.
• W2150970912 sameAs 2150970912 @default.
• W2150970912 citedByCount "0" @default.
• W2150970912 crossrefType "journal-article" @default.
• W2150970912 hasAuthorship W2150970912A5015399688 @default.
• W2150970912 hasAuthorship W2150970912A5059993695 @default.
• W2150970912 hasBestOaLocation W21509709121 @default.
• W2150970912 hasConcept C104317684 @default.
• W2150970912 hasConcept C126322002 @default.
• W2150970912 hasConcept C135763542 @default.
• W2150970912 hasConcept C153209595 @default.
• W2150970912 hasConcept C159654299 @default.
• W2150970912 hasConcept C198451711 @default.
• W2150970912 hasConcept C203014093 @default.
• W2150970912 hasConcept C2776232647 @default.
• W2150970912 hasConcept C2777575956 @default.
• W2150970912 hasConcept C2779356809 @default.
• W2150970912 hasConcept C55493867 @default.
• W2150970912 hasConcept C71924100 @default.
• W2150970912 hasConcept C86803240 @default.
• W2150970912 hasConceptScore W2150970912C104317684 @default.
• W2150970912 hasConceptScore W2150970912C126322002 @default.
• W2150970912 hasConceptScore W2150970912C135763542 @default.
• W2150970912 hasConceptScore W2150970912C153209595 @default.
• W2150970912 hasConceptScore W2150970912C159654299 @default.
• W2150970912 hasConceptScore W2150970912C198451711 @default.
• W2150970912 hasConceptScore W2150970912C203014093 @default.
• W2150970912 hasConceptScore W2150970912C2776232647 @default.
• W2150970912 hasConceptScore W2150970912C2777575956 @default.
• W2150970912 hasConceptScore W2150970912C2779356809 @default.
• W2150970912 hasConceptScore W2150970912C55493867 @default.
• W2150970912 hasConceptScore W2150970912C71924100 @default.
• W2150970912 hasConceptScore W2150970912C86803240 @default.
• W2150970912 hasIssue "5" @default.
• W2150970912 hasLocation W21509709121 @default.
• W2150970912 hasLocation W21509709122 @default.
• W2150970912 hasLocation W21509709123 @default.
• W2150970912 hasOpenAccess W2150970912 @default.
• W2150970912 hasPrimaryLocation W21509709121 @default.
• W2150970912 hasRelatedWork W1978435955 @default.
• W2150970912 hasRelatedWork W2023721760 @default.
• W2150970912 hasRelatedWork W2043104746 @default.
• W2150970912 hasRelatedWork W2150970912 @default.
• W2150970912 hasRelatedWork W2155117280 @default.
• W2150970912 hasRelatedWork W2161441772 @default.
• W2150970912 hasRelatedWork W2350091741 @default.
• W2150970912 hasRelatedWork W2355496750 @default.
• W2150970912 hasRelatedWork W2412341873 @default.
• W2150970912 hasRelatedWork W569569844 @default.
• W2150970912 hasVolume "12" @default.
• W2150970912 isParatext "false" @default.
• W2150970912 isRetracted "false" @default.
• W2150970912 magId "2150970912" @default.
• W2150970912 workType "article" @default.